Central sympathetic inhibition to reduce postablation atrial fibrillation recurrences in hypertensive patients: A randomized, controlled study

Circulation

Volumn 130, Issue 16, 2014, Pages 1346-1352

  Giannopoulos, Georgios ^a   Kossyvakis, Charalampos ^a   Efremidis, Michael ^b   Katsivas, Apostolos ^c   Panagopoulou, Vasiliki ^d   Doudoumis, Konstantinos ^a   Raisakis, Konstantinos ^a   Letsas, Konstantinos ^b   Rentoukas, Ilias ^a   Pyrgakis, Vlasios ^a   Manolis, Antonis S ^d   Tousoulis, Dimitrios ^d   Stefanadis, Christodoulos ^d   Deftereos, Spyridon ^a  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c RED CROSS HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Hypertension; Moxonidine

Indexed keywords

ANTIHYPERTENSIVE AGENT; MOXONIDINE; THROMBIN; IMIDAZOLE DERIVATIVE;

ABLATION CATHETER; ABLATION THERAPY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIAC MAPPING SYSTEM; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; FALSE ANEURYSM; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TAMPONADE; HEMATOMA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PAROXYSMAL HEART ATRIUM FIBRILLATION; PERICARDIOCENTESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY VEIN ISOLATION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RECURRENT DISEASE; RESPIRATORY TRACT INTUBATION; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; ADRENERGIC SYSTEM; AGED; ATRIAL FIBRILLATION; CATHETER ABLATION; COMPLICATION; DRUG EFFECTS; FOLLOW UP; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 84925229679     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.010999     Document Type: Article

References (31)

1. Chen PS, Tan AY. Autonomic nerve activity and atrial fibrillation. Heart Rhythm. 2007;4(3 suppl):S61-S64.
2. Shen MJ, Zipes DP. Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res. 2014;114:1004-1021.
3. Sharifov OF, Fedorov VV, Beloshapko GG, Glukhov AV, Yushmanova AV, Rosenshtraukh LV. Roles of adrenergic and cholinergic stimulation in spontaneous atrial fibrillation in dogs. J Am Coll Cardiol. 2004;43:483-490.
4. Shen MJ, Choi EK, Tan AY, Lin SF, Fishbein MC, Chen LS, Chen PS. Neural mechanisms of atrial arrhythmias. Nat Rev Cardiol. 2012;9:30-39.
5. Linz D, Mahfoud F, Schotten U, Ukena C, Neuberger HR, Wirth K, Böhm M. Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. Hypertension. 2012;60:172-178.
6. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Baranova V, Turov A, Shirokova N, Karaskov A, Mittal S, Steinberg JS. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012;60:1163-1170.
7. Deftereos S, Giannopoulos G, Kossyvakis C, Efremidis M, Panagopoulou V, Raisakis K, Kaoukis A, Karageorgiou S, Bouras G, Katsivas A, Pyrgakis V, Stefanadis C. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients. Am J Cardiol. 2013;112:684-687.
8. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA 3rd, Page RL, Ezekowitz MD, Slotwiner DJ, Jackman WM, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Le Heuzey JY, Crijns HJ, Lowe JE, Curtis AB, Olsson S, Ellenbogen KA, Prystowsky EN, Halperin JL, Tamargo JL, Kay GN, Wann LS, Jacobs AK, Anderson JL, Albert N, Hochman JS, Buller CE, Kushner FG, Creager MA, Ohman EM, Ettinger SM, Stevenson WG, Guyton RA, Tarkington LG, Halperin JL, Yancy CW; 2006 Writing Committee Members; ACCF/AHA Task Force Members. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm. 2011;8:157-176.
9. Coumel P, Attuel P, Lavallée J, Flammang D, Leclercq JF, Slama R. The atrial arrhythmia syndrome of vagal origin [in French]. Arch Mal Coeur Vaiss. 1978;71:645-656.
10. Huang JL, Wen ZC, Lee WL, Chang MS, Chen SA. Changes of autonomic tone before the onset of paroxysmal atrial fibrillation. Int J Cardiol. 1998;66:275-283.
11. Levy MN. Sympathetic-parasympathetic interactions in the heart. Circ Res. 1971;29:437-445.
12. Stramba-Badiale M, Vanoli E, De Ferrari GM, Cerati D, Foreman RD, Schwartz PJ. Sympathetic-parasympathetic interaction and accentuated antagonism in conscious dogs. Am J Physiol. 1991;260(2 pt 2):H335-H340.
13. Tomita T, Takei M, Saikawa Y, Hanaoka T, Uchikawa S, Tsutsui H, Aruga M, Miyashita T, Yazaki Y, Imamura H, Kinoshita O, Owa M, Kubo K. Role of autonomic tone in the initiation and termination of paroxysmal atrial fibrillation in patients without structural heart disease. J Cardiovasc Electrophysiol. 2003;14:559-564.
14. Zimmermann M, Kalusche D. Fluctuation in autonomic tone is a major determinant of sustained atrial arrhythmias in patients with focal ectopy originating from the pulmonary veins. J Cardiovasc Electrophysiol. 2001;12:285-291.
15. Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation. 2002;105:2753-2759.
16. Amar D, Zhang H, Miodownik S, Kadish AH. Competing autonomic mechanisms precede the onset of postoperative atrial fibrillation. J Am Coll Cardiol. 2003;42:1262-1268.
17. Katritsis DG, Giazitzoglou E, Zografos T, Pokushalov E, Po SS, Camm AJ. Rapid pulmonary vein isolation combined with autonomic ganglia modification: a randomized study. Heart Rhythm. 2011;8:672-678.
18. Katritsis D, Giazitzoglou E, Sougiannis D, Goumas N, Paxinos G, Camm AJ. Anatomic approach for ganglionic plexi ablation in patients with paroxysmal atrial fibrillation. Am J Cardiol. 2008;102:330-334.
19. Lemola K, Chartier D, Yeh YH, Dubuc M, Cartier R, Armour A, Ting M, Sakabe M, Shiroshita-Takeshita A, Comtois P, Nattel S. Pulmonary vein region ablation in experimental vagal atrial fibrillation: role of pulmonary veins versus autonomic ganglia. Circulation. 2008;117:470-477.
20. Scanavacca M, Pisani CF, Hachul D, Lara S, Hardy C, Darrieux F, Trombetta I, Negrão CE, Sosa E. Selective atrial vagal denervation guided by evoked vagal reflex to treat patients with paroxysmal atrial fibrillation. Circulation. 2006;114:876-885.
21. Lemery R, Birnie D, Tang AS, Green M, Gollob M. Feasibility study of endocardial mapping of ganglionated plexuses during catheter ablation of atrial fibrillation. Heart Rhythm. 2006;3:387-396.
22. Pokushalov E, Romanov A, Shugayev P, Artyomenko S, Shirokova N, Turov A, Katritsis DG. Selective ganglionated plexi ablation for paroxysmal atrial fibrillation. Heart Rhythm. 2009;6:1257-1264.
23. Katritsis DG, Pokushalov E, Romanov A, Giazitzoglou E, Siontis GC, Po SS, Camm AJ, Ioannidis JP. Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial. J Am Coll Cardiol. 2013;62:2318-2325.
24. Báez-Escudero JL, Keida T, Dave AS, Okishige K, Valderrábano M. Ethanol infusion in the vein of Marshall leads to parasympathetic denervation of the human left atrium: implications for atrial fibrillation. J Am Coll Cardiol. 2014;63:1892-1901.
25. Rajendran PS, Buch E, Shivkumar K. Marshaling the autonomic nervous system for treatment of atrial fibrillation. J Am Coll Cardiol. 2014;63:1902-1903.
26. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha- Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-1401.
27. Edwards LP, Brown-Bryan TA, McLean L, Ernsberger P. Pharmacological properties of the central antihypertensive agent, moxonidine. Cardiovasc Ther. 2012;30:199-208.
28. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ; MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5:659-667.
29. Takigawa M, Takahashi A, Kuwahara T, Okubo K, Takahashi Y, Watari Y, Takagi K, Fujino T, Kimura S, Hikita H, Tomita M, Hirao K, Isobe M. Long-term follow-up after catheter ablation of paroxysmal atrial fibrillation: the incidence of recurrence and progression of atrial fibrillation. Circ Arrhythm Electrophysiol. 2014;7:267-273.
30. Deftereos S, Giannopoulos G, Efremidis M, Kossyvakis C, Katsivas A, Panagopoulou V, Papadimitriou C, Karageorgiou S, Doudoumis K, Raisakis K, Kaoukis A, Alexopoulos D, Manolis AS, Stefanadis C, Cleman MW. Colchicine for prevention of atrial fibrillation recurrence after pulmonary vein isolation: mid-term efficacy and effect on quality of life. Heart Rhythm. 2014;11:620-628.
31. Andrade JG, Khairy P, Macle L, Packer DL, Lehmann JW, Holcomb RG, Ruskin JN, Dubuc M. Incidence and significance of early recurrences of atrial fibrillation after cryoballoon ablation: insights from the multicenter Sustained Treatment of Paroxysmal Atrial Fibrillation (STOP AF) Trial. Circ Arrhythm Electrophysiol. 2014;7:69-75.